The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Discovery of the Dual Orexin Receptor Antagonist [(7 R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2 H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the Treatment of Insomnia
Open accessAbstract
Despite increased understanding of the biological basis for sleep control in the brain, few novel mechanisms for the treatment of insomnia have been identified in recent years. One notable exception is inhibition of the excitatory neuropeptides orexins A and B by design of orexin receptor antagonists. Herein, we describe how efforts to understand the origin of poor oral pharmacokinetics in a leading HTS-derived diazepane orexin receptor antagonist led to the identification of compound 10 with a 7-methyl substitution on the diazepane core. Though 10 displayed good potency, improved pharmacokinetics, and excellent in vivo efficacy, it formed reactive metabolites in microsomal incubations. A mechanistic hypothesis coupled with an in vitro assay to assess bioactivation led to replacement of the fluoroquinazoline ring of 10 with a chlorobenzoxazole to provide 3 (MK-4305), a potent dual orexin receptor antagonist that is currently being tested in phase III clinical trials for the treatment of primary insomnia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H., Williams, S. C., Richardson, J. A., Kozlowski, G. P., Wilson, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)80949-6 · Cited by 5,501
The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity
de Lecea, L., Kilduff, T. S., Peyron, C., Gao, X.-B., Foye, P. E., Danielson, P. E., Fukuhara, C., Battenberg, E. L. F., Gautvik, V. T., Bartlett, F. S., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.322 · Cited by 3,878
Narcolepsy in orexin Knockout Mice
Chemelli, R. M., Willie, J. T., Sinton, C. M., Elmquist, J. K., Scammell, T., Lee, C., Richardson, J. A., Williams, S. C., Xiong, Y., Kisanuki, Y., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)81973-x · Cited by 3,095
Lin, L., Faraco, J., Li, R., Kadotani, H., Rogers, W., Lin, X., Qiu, X., de Jong, P. J., Nishino, S., & Mignot, E. (1999) · Cell · doi:10.1016/s0092-8674(00)81965-0 · Cited by 2,613
Reduced Number of Hypocretin Neurons in Human Narcolepsy
Thannickal, T. C., Moore, R. Y., Nienhuis, R., Ramanathan, L., Gulyani, S., Aldrich, M., Cornford, M., & Siegel, J. M. (2000) · Neuron · doi:10.1016/s0896-6273(00)00058-1 · Cited by 2,089
Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., & Baillie, T. A. (2004) · Chemical Research in Toxicology · doi:10.1021/tx034170b · Cited by 706
Distinct Narcolepsy Syndromes in Orexin Receptor-2 and Orexin Null Mice
Willie, J. T., Chemelli, R. M., Sinton, C. M., Tokita, S., Williams, S. C., Kisanuki, Y. Y., Marcus, J. N., Lee, C., Elmquist, J. K., Kohlmeier, K. A., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00330-1 · Cited by 645
Promotion of sleep by targeting the orexin system in rats, dogs and humans
Brisbare-Roch, C., Dingemanse, J., Koberstein, R., Hoever, P., Aissaoui, H., Flores, S., Mueller, C., Nayler, O., van Gerven, J., de Haas, S. L., et al. (2007) · Nature Medicine · doi:10.1038/nm1544 · Cited by 573
Daley, M., Morin, C. M., LeBlanc, M., Grégoire, J. P., Savard, J., & Baillargeon, L. (2009) · Sleep Medicine · doi:10.1016/j.sleep.2008.04.005 · Cited by 440
Varma, M. V. S., & Panchagnula, R. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.04.003 · Cited by 361
Concomitant loss of dynorphin, NARP, and orexin in narcolepsy
Crocker, A., España, R. A., Papadopoulou, M., Saper, C. B., Faraco, J., Sakurai, T., Honda, M., Mignot, E., & Scammell, T. E. (2005) · Neurology · doi:10.1212/01.wnl.0000168173.71940.ab · Cited by 301
Dugovic, C., Shelton, J. E., Aluisio, L. E., Fraser, I. C., Jiang, X., Sutton, S. W., Bonaventure, P., Yun, S., Li, X., Lord, B., et al. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.152009 · Cited by 230
Narp immunostaining of human hypocretin (orexin) neurons: Loss in narcolepsy
Blouin, A. M., Thannickal, T. C., Worley, P. F., Baraban, J. M., Reti, I. M., & Siegel, J. M. (2005) · Neurology · doi:10.1212/01.wnl.0000175219.01544.c8 · Cited by 167
(1999) · CRC Press eBooks · doi:10.1201/b13995 · Cited by 148
Ramelteon for the treatment of insomnia
Borja‐Hart, N., & Daniel, K. L. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.10.016 · Cited by 113
Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time
Wafford, K. A., & Ebert, B. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2464 · Cited by 111
Diagnosis and treatment of insomnia
Passarella, S., & Duong, M.-T. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060640 · Cited by 97
Orexin Receptor Antagonists: Medicinal Chemistry and Therapeutic Potential
Roecker, A. J., & Coleman, P. J. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608784936746 · Cited by 91
Self-citationKunapuli, P., Ransom, R. W., Murphy, K. L., Pettibone, D. J., Kerby, J., Grimwood, S., Zuck, P. D., Hodder, P., Lacson, R., Hoffman, I., et al. (2003) · Analytical Biochemistry · doi:10.1016/s0003-2697(02)00587-0 · Cited by 85
Self-citationSelective stimulation of orexin receptor type 2 promotes wakefulness in freely behaving rats
Akanmu, M. A., & Honda, K. (2005) · Brain Research · doi:10.1016/j.brainres.2005.04.064 · Cited by 81
Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX2R) antagonists
McAtee, L. C., Sutton, S. W., Rudolph, D. A., Li, X., Aluisio, L. E., Phuong, V. K., Dvorak, C. A., Lovenberg, T. W., Carruthers, N. I., & Jones, T. K. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.06.032 · Cited by 77
Whitman, D. B., Cox, C. D., Breslin, M. J., Brashear, K. M., Schreier, J. D., Bogusky, M. J., Bednar, R. A., Lemaire, W., Bruno, J. G., Hartman, G. D., et al. (2009) · ChemMedChem · doi:10.1002/cmdc.200900069 · Cited by 74
Self-citationBiomedical Application of Orexin/Hypocretin Receptor Ligands in Neuroscience
Boss, C., Roch, C., & Jenck, F. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801296d · Cited by 72
Proline bis-amides as potent dual orexin receptor antagonists
Bergman, J. M., Roecker, A. J., Mercer, S. P., Bednar, R. A., Reiss, D. R., Ransom, R. W., Harrell, C. M., Pettibone, D. J., Lemaire, W., Murphy, K. L., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.01.001 · Cited by 70
Self-citationOrexin receptor antagonists: a review of promising compounds patented since 2006
Coleman, P. J., & Renger, J. J. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903567085 · Cited by 61
Self-citationCox, C. D., McGaughey, G. B., Bogusky, M. J., Whitman, D. B., Ball, R. G., Winrow, C. J., Renger, J. J., & Coleman, P. J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.04.026 · Cited by 60
Self-citationHypocretins (orexins): clinical impact of the discovery of a neurotransmitter
Baumann, C. R., & Bassetti, C. L. (2005) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2005.01.005 · Cited by 58
Efficacy and clinical safety of ramelteon: An evidence-based review
Sateia, M. J., Kirby-Long, P., & Taylor, J. L. (2008) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2007.12.005 · Cited by 51
Emerging drugs for insomnia: new frontiers for old and novel targets
Sullivan, S. S., & Guilleminault, C. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903171948 · Cited by 50
N-Glycine-sulfonamides as potent dual orexin 1/orexin 2 receptor antagonists
Aissaoui, H., Koberstein, R., Zumbrunn, C., Gatfield, J., Roch, C., Jenck, F., Treiber, A., & Boss, C. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.09.079 · Cited by 29
Coleman, P. J., Schreier, J. D., Roecker, A. J., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.05.047 · Cited by 27
Self-citationAntagonists of the orexin receptors
Cai, J., Cooke, F. E., & Sherborne, B. S. (2006) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.16.5.631 · Cited by 15
Chapter 5 Recent Advances in the Treatment of Insomnia
Palomer, A., Príncep, M., & Guglietta, A. (2007) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(07)42005-x · Cited by 12
Alvariño, F., Monti, J. M., Jantos, H., & Monti, D. (1999) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x1999000800011 · Cited by 4
Cited by
Click Chemistry: 1,2,3‐Triazoles as Pharmacophores
Agalave, S. G., Maujan, S. R., & Pore, V. S. (2011) · Chemistry – An Asian Journal · doi:10.1002/asia.201100432 · Cited by 1,305
The role of orexin in motivated behaviours
Sakurai, T. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3837 · Cited by 464
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
Atkin, T., Comai, S., & Gobbi, G. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014381 · Cited by 391
Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials
Herring, W. J., Connor, K. M., Ivgy-May, N., Snyder, E., Liu, K., Snavely, D. B., Krystal, A. D., Walsh, J. K., Benca, R. M., Rosenberg, R., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.10.003 · Cited by 300
Promotion of Sleep by Suvorexant—A Novel Dual Orexin Receptor Antagonist
Winrow, C. J., Gotter, A. L., Cox, C. D., Doran, S. M., Tannenbaum, P. L., Breslin, M. J., Garson, S. L., Fox, S. V., Harrell, C. M., Stevens, J., et al. (2011) · Journal of Neurogenetics · doi:10.3109/01677063.2011.566953 · Cited by 269
Self-citation
Metadata
- Authors
- Cox, C. D., Breslin, M. J., Whitman, D. B., Schreier, J. D., McGaughey, G. B., Bogusky, M. J., Roecker, A. J., Mercer, S. P., Bednar, R. A., Lemaire, W., Bruno, J. G., Reiss, D. R., Harrell, C. M., Murphy, K. L., Garson, S. L., Doran, S. M., Prueksaritanont, T., Anderson, W. B., Tang, C., Roller, S., Cabalu, T. D., Cui, D., Hartman, G. D., Young, S. D., Koblan, K. S., Winrow, C. J., Renger, J. J., & Coleman, P. J.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2010-06-21
- Volume
- 53
- Issue
- 14
- Pages
- 5320-5332
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2018441208
- Cited by
- 379
- References
- 34
- FWCI
- 27.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
